Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$1.04B |
| 2 |
Chevron
CVX
|
+$820M |
| 3 |
Shopify
SHOP
|
+$599M |
| 4 |
Berkshire Hathaway Class B
BRK.B
|
+$539M |
| 5 |
Meta Platforms (Facebook)
META
|
+$479M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$675M |
| 2 |
Tesla
TSLA
|
+$661M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$633M |
| 4 |
Verizon
VZ
|
+$533M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$377M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.41% |
| 2 | Technology | 16.8% |
| 3 | Consumer Staples | 11.12% |
| 4 | Consumer Discretionary | 10.11% |
| 5 | Financials | 8.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3376
Ebang International Holdings
EBON
$12.2M
| $343K | ﹤0.01% |
28,553
+12,783
| +81% | +$312K |
|
3377
Roivant Sciences
ROIV
$26.2B
| $343K | ﹤0.01% |
+84,300
| New | +$335K |
|
|
TYME
3378
DELISTED
Tyme Technologies, Inc. Common Stock
TYME
| $343K | ﹤0.01% |
1,226,721
-34,090
| -3% | -$9.83K |
|
3379
Ceragon Networks
CRNT
$201M
| $342K | ﹤0.01% |
133,200
-520,935
| -80% | -$994K |
|
3380
iShares JPMorgan EM Local Currency Bond ETF
LEMB
$723M
| $342K | ﹤0.01% |
10,000
+4,000
| +67% | +$140K |
|
3381
Belpointe PREP
OZ
$184M
| $342K | ﹤0.01% |
3,500
-4,000
| -53% | -$396K |
|
3382
State Street SPDR S&P 400 Mid Cap Growth ETF
MDYG
$2.97B
| $341K | ﹤0.01% |
+5,600
| New | +$377K |
|
|
VRPX
3383
DELISTED
Virpax Pharmaceuticals, Inc. Common Stock
VRPX
| $341K | ﹤0.01% |
813
+187
| +30% | +$76.7K |
|
|
CBIO
3384
Crescent Biopharma
CBIO
$621M
| $339K | ﹤0.01% |
5,664
+958
| +20% | +$70.9K |
|
3385
Taylor Devices
TAYD
$173M
| $338K | ﹤0.01% |
38,862
+2,300
| +6% | +$21.1K |
|
|
MILE
3386
DELISTED
Metromile, Inc. Common Stock
MILE
| $338K | ﹤0.01% |
368,500
-104,700
| -22% | -$107K |
|
3387
Apogee Enterprises
APOG
$888M
| $337K | ﹤0.01% |
+8,600
| New | +$368K |
|
3388
The Beachbody Company
BODI
$46.6M
| $337K | ﹤0.01% |
+5,614
| New | +$455K |
|
|
AWH
3389
DELISTED
Aspira Women's Health Inc. Common Stock
AWH
| $337K | ﹤0.01% |
38,214
-37,306
| -49% | -$379K |
|
|
ITRG
3390
Integra Resources
ITRG
$554M
| $336K | ﹤0.01% |
129,160
-44,000
| -25% | -$121K |
|
3391
Arq
ARQ
$101M
| $336K | ﹤0.01% |
71,645
+7,641
| +12% | +$41.6K |
|
|
EXTN
3392
DELISTED
Exterran Corporation
EXTN
| $336K | ﹤0.01% |
78,100
+65,900
| +540% | +$399K |
|
3393
iShares US Utilities ETF
IDU
$1.37B
| $334K | ﹤0.01% |
3,900
-4,800
| -55% | -$424K |
|
3394
RPAR Risk Parity ETF
RPAR
$584M
| $334K | ﹤0.01% |
17,100
+5,623
| +49% | +$120K |
|
|
SRRA
3395
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $334K | ﹤0.01% |
6,074
-86,400
| -93% | -$4.53M |
|
3396
Fulcrum Therapeutics
FULC
$285M
| $333K | ﹤0.01% |
+68,000
| New | +$665K |
|
3397
GeoVax Labs
GOVX
$3.84M
| $333K | ﹤0.01% |
+1,071
| New | +$472K |
|
|
INVX
3398
Innovex International
INVX
$2.16B
| $333K | ﹤0.01% |
12,900
-200
| -2% | -$6.09K |
|
3399
Alkami Technology
ALKT
$2.19B
| $332K | ﹤0.01% |
23,900
-190,100
| -89% | -$2.4M |
|
3400
Bridgeline Digital
BLIN
$13.9M
| $329K | ﹤0.01% |
274,417
-51,783
| -16% | -$73.5K |
|
Similar funds
Jim Simons's Q2 2022 Portfolio in Review
As of Q2 2022, Jim Simons held 4,738 positions worth $84.5B, down 0.87% from $85.2B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Jim Simons deployed $13.7B of net new capital in Q2 2022, opening 694 new positions and adding to 1,955 existing holdings. Its largest new stake was Microsoft: 3,820,133 shares worth $981M.
By sector, the portfolio is most concentrated in Healthcare at 19% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Staples.
On the sell side, the largest reduction was Tesla, an estimated $661M trimmed.
- Jim Simons's largest Q2 2022 buy was Microsoft: 3,820,133 shares worth $981M.
- Jim Simons added most to Chevron in Q2 2022, an estimated $820M increase.
- Jim Simons's biggest Q2 2022 reduction was Tesla, cutting an estimated $661M.
- Jim Simons fully exited Amazon in Q2 2022, selling an estimated $675M.
- Jim Simons's ten largest holdings make up 11% of its $84.5B portfolio in Q2 2022.
- Jim Simons opened 694 new positions and closed 562 in Q2 2022.
- Jim Simons's portfolio value fell 0.87% quarter-over-quarter to $84.5B.
Based on Renaissance Technologies's 13F filing for Q2 2022, filed 12 Aug 2022.